[Automatic implantable cardioverter-defibrillator ( @entity737 ) and antitachycardia pacemaker (Tachylog 651) in the treatment of XXXX ].

@entity1 @entity296 @entity1165 @entity301 @entity55 @entity10804 @entity737 @entity591 @entity2224 @entity299
For the electrotherapy of refractory @entity1165 the @entity737 ( @entity737 ) and antitachycardia pacemaker are available. The long-term use of antitachycardia pacing is still limited by the potential risk of acceleration to @entity2224 . To combine the advantages of antitachycardia pacing with back-up defibrillation, we evaluated the use of an antitachycardia pacemaker with the @entity10804 . The @entity737 was implanted in 13 @entity1 with a mean age of 62 years (from 46 to 75 years); six of them with recurrent @entity1165 (170 +/- 16 per minute) which could reliably be terminated by overdrive pacing, received also an antitachycardia pacemaker (Tachylog 651). The underlying @entity299 was @entity301 in 11 @entity1 and @entity296 in 2 cases. All @entity1 had survived 1 to 6 cardiac arrests and had not responded to 6 +/- 1.5 antiarrhythmic drugs. For antitachycardia pacing we used burst stimulation with 4 to 6 stimuli and coupling intervals from 260 to 300 ms. During the follow-up period of 12 +/- 2 months, 83% of 744 @entity591 could be terminated by burst stimulation, according to the diagnostic data of the pulse generator. If the pacemaker failed to terminate or in case of acceleration (three @entity1 ), the automatic countershock of the @entity737 (5-42 per @entity1 ) restored sinus rhythm. In seven @entity1 with high rate @entity591 , 2 to 69 @entity737 discharges occurred. No @entity1 died suddenly, but three died due to underlying disease and one because of a @entity55 postoperatively. Future antitachycardia devices should be flexible with regard to detection and termination modes, combining antitachycardia pacing with back-up defibrillation.
